PA

Perceptive Advisors Portfolio holdings

AUM $6.66B Turnover 32.23%
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+19.62%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3B
AUM Growth
-$457M
Cap. Flow
-$196M
Cap. Flow %
-6.55%
Top 10 Hldgs %
45.74%
Holding
112
New
17
Increased
23
Reduced
25
Closed
15
Avg Time Held Equity + Options
2.2 years
Top 10 Avg Time Held Equity + Options
1.4 years
Top 20 Avg Time Held Equity + Options
1.5 years
Avg Time Held Equity only
2.4 years
Top 10 Avg Time Held Equity only
1.4 years
Top 20 Avg Time Held Equity only
1.5 years

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$40.3M
2
ARGX icon
argenx
ARGX
+$39.9M
3
RVMD icon
Revolution Medicines
RVMD
+$39.2M
4
IMVT icon
Immunovant
IMVT
+$29.2M
5
RYZB icon
RayzeBio, Inc. Common Stock
RYZB
+$16.3M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$68.3M
2
VIR icon
Vir Biotechnology
VIR
+$48M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$46.2M
4
APLS icon
Apellis Pharmaceuticals
APLS
+$35.7M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$33.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.21%
2 Miscellaneous 0.79%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ILMN icon
101
Illumina
ILMN
$41B
– –
-149,060
Closed -$27.2M –
QTRX icon
102
Quanterix
QTRX
$145M
– –
-130,000
Closed -$2.93M –
TERN icon
103
PUT
DELISTED
Terns Pharmaceuticals
TERN
– –
-1,075,000
Closed -$9.41M –
VIR icon
104
Vir Biotechnology
VIR
$1.76B
– –
-1,958,264
Closed -$48M –
VKTX icon
105
Viking Therapeutics
VKTX
$3.24B
– –
-441,147
Closed -$6.31M –
VRNA
106
CALL
DELISTED
Verona Pharma
VRNA
– –
-500,000
Closed -$675K –
XBI icon
107
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.71B
– –
-150,000
Closed -$138K –
ITCI icon
108
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-245,800
Closed -$15.6M –
MRTX
109
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-200,000
Closed -$690K –
MRTX
110
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-719,103
Closed -$26M –
RETA
111
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-670,206
Closed -$68.3M –
ISEE
112
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-168,000
Closed -$6.61M –
1 2 3 4
5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Perceptive Advisors held 112 positions worth $3B, down 13% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $196M in Q3 2023, closing 15 positions and reducing 25 holdings. Its most notable exit was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $68.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Perceptive Advisors opened a new position in Apogee Therapeutics worth $38.9M.

  • Perceptive Advisors's largest Q3 2023 buy was Apogee Therapeutics: 1,827,901 shares worth $38.9M.
  • Perceptive Advisors added most to argenx in Q3 2023, an estimated $39.9M increase.
  • Perceptive Advisors's biggest Q3 2023 reduction was Amylyx Pharmaceuticals, cutting an estimated $46.2M.
  • Perceptive Advisors fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $68.3M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $3B portfolio in Q3 2023.
  • Perceptive Advisors opened 17 new positions and closed 15 in Q3 2023.
  • Perceptive Advisors's portfolio value fell 13% quarter-over-quarter to $3B.

Based on Perceptive Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.